National Health Challenge Lung cancer is the leading cause of cancer death in China, with over one million new cases annually. The majority of patients are still diagnosed at late stages when curative treatment is no longer possible, making improved early detection a national health priority.
Protocol Scope This paper describes the China Protocol - a comprehensive, multi-technology system for lung cancer early screening, precise diagnosis, and individualized treatment. It integrates low-dose CT (LDCT) screening with AI-enhanced image analysis, blood-based ctDNA methylation testing, and refined staging criteria.
Key Technologies The protocol features three innovations: the Tre-LDCT imaging technology with associated C-Lung-RADS reporting system, the LunaCAM ctDNA methylation liquid biopsy models (LunaCAM-S for screening and LunaCAM-D for diagnosis), and a refined staging system that formally recognizes ultra-early stage lung cancer.
Population Impact By applying this protocol, the proportion of lung cancer cases detected at an early stage increased from 46.3% to 65.6%. Five-year survival rates reached 90.4% for early-stage and 97.5% for ultra-early stage patients, demonstrating the profound survival benefit of the integrated approach.
Tre-LDCT Technology Tre-LDCT is an enhanced LDCT protocol that improves image quality while maintaining low radiation doses. It incorporates AI-assisted nodule detection and characterization algorithms that identify suspicious findings more comprehensively than standard radiologist review alone.
C-Lung-RADS System The China Lung Cancer Reporting and Data System (C-Lung-RADS) is a structured reporting framework adapted specifically for the Chinese population. It demonstrated 87.1% sensitivity for lung cancer detection, compared to 63.3% for the standard Lung-RADS system used in Western populations.
Population-Specific Calibration The significant sensitivity gap between C-Lung-RADS and standard Lung-RADS reflects the fact that lung cancer epidemiology in China differs from Western populations - with higher rates in non-smokers and adenocarcinoma subtype predominance - requiring recalibration of nodule classification thresholds.
AI-Assisted Detection Deep learning algorithms were integrated into the Tre-LDCT pipeline to flag suspicious nodules, reduce false negatives, and provide quantitative measurements of nodule characteristics. This reduces the burden on radiologists and improves consistency in the high-volume screening setting.
ctDNA Methylation as a Biomarker Cell-free circulating tumor DNA (ctDNA) in plasma carries tumor-specific methylation signatures that can be detected by sensitive sequencing. Lung cancer cells shed ctDNA with characteristic methylation patterns that distinguish them from normal tissue, enabling blood-based cancer detection.
LunaCAM-S for Screening LunaCAM-S is a ctDNA methylation model developed for population-level lung cancer screening. It achieved an AUC of 0.90, indicating strong ability to distinguish lung cancer cases from healthy individuals in a blood test that can complement or follow up LDCT screening.
LunaCAM-D for Diagnosis LunaCAM-D is optimized for diagnostic settings where a suspicious lung nodule has been identified and a non-invasive test is needed to clarify malignancy before biopsy. It achieved an AUC of 0.81, supporting its use as an adjunct to imaging in characterizing indeterminate nodules.
Integration with Imaging The protocol recommends using LunaCAM-S and LunaCAM-D in conjunction with CT imaging rather than as standalone tests. This multi-modal approach improves sensitivity while maintaining specificity, allowing more confident management decisions for patients with indeterminate findings.
Ultra-Early Stage Redefinition The China Protocol formally redefines Stage IA1 as an ultra-early stage category, recognizing that very small, minimally invasive adenocarcinomas have fundamentally different prognoses and treatment requirements from larger Stage IA tumors. This reclassification enables more precise treatment planning.
Dramatic Stage Migration Implementation of the protocol shifted the stage distribution of diagnosed lung cancers from 46.3% early-stage to 65.6% early-stage. This represents a massive improvement in detection timing, with a corresponding reduction in late-stage diagnoses.
Survival Outcomes The 5-year survival rate for early-stage lung cancer patients detected through the protocol reached 90.4%, and for ultra-early stage patients it reached 97.5%. These figures approach the survival rates of other early-detected cancers and represent a major improvement over historically poor lung cancer outcomes.
Population-Level Impact Scaling the protocol nationally has the potential to prevent hundreds of thousands of lung cancer deaths annually in China by ensuring that tumors are found while they are still surgically curable rather than after metastatic spread has occurred.
Surgery for Early-Stage Disease The protocol emphasizes minimally invasive surgery - video-assisted thoracoscopic surgery (VATS) and robotic approaches - as the treatment of choice for early-stage cancers detected by screening. Precise preoperative staging guides the extent of resection and nodal dissection.
Ablation for Ultra-Early Stage For ultra-early Stage IA1 patients who are poor surgical candidates, the protocol endorses image-guided thermal ablation as a curative-intent alternative, reflecting a personalized approach that matches treatment intensity to disease biology and patient fitness.
Systemic Therapy Guidance For patients found to have more advanced disease, the protocol integrates comprehensive genomic profiling to identify driver mutations (EGFR, ALK, ROS1, MET, etc.) that match to approved targeted therapies, ensuring that systemic treatment decisions are molecularly guided.
Chinese Population Considerations The individualized treatment recommendations account for the higher prevalence of EGFR mutations in Chinese non-smoking lung cancer patients compared to Western populations, reflecting an evidence base derived from Asian clinical trials and real-world data.
National Rollout The immediate priority is scaling the China Protocol from demonstration sites to nationwide implementation, requiring training of radiologists, pulmonologists, and thoracic surgeons in the integrated approach, as well as infrastructure for ctDNA testing at population scale.
Refinement of ctDNA Models Ongoing collection of screening cohort outcomes will enable iterative refinement of LunaCAM-S and LunaCAM-D with larger training datasets, potentially improving their sensitivity and specificity and reducing the number of unnecessary follow-up procedures.
Adaptation for Other Populations While the China Protocol was developed for and validated in Chinese populations, its core principles - AI-enhanced LDCT, liquid biopsy integration, and refined staging - are broadly applicable. Adaptation studies for other high-incidence populations could extend its impact globally.
Cost-Effectiveness Analysis Formal health economic analysis of the protocol is needed to inform policy decisions about national screening program implementation. The high early-stage detection rate and survival improvement must be weighed against the cost of large-scale LDCT screening and liquid biopsy testing.